Epidemiology of bone and soft tissue sarcomas.

Abstract:

:Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. This is particularly true of radiation-induced sarcomas because patients who develop this malignancy seem to have a poor prognosis. As more patients survive their malignancies, we may see an increase in the incidence of postradiation sarcomas. Therefore, patients who receive radiation should be monitored closely, and a high index of suspicion should be maintained for complaints referable to the irradiated site. The role of various chemical agents in the development of sarcomas needs further definition, as the literature is replete with conflicting reports. Problems exist in that we are dealing with a variety of agents with different levels of exposure, possibly resulting in different types of neoplasms. Additionally, many of the agents in question are not pure substances, but frequently are contaminated with other potentially carcinogenic agents. Finally, the majority of studies reported are from different countries. Thus, there may be unidentified operative genetic and environmental factors. The recent advances in cytogenetics and molecular biology have already resulted in a significant increase in information related to bone and soft tissue sarcomas. Many chromosomal abnormalities identified will have diagnostic, prognostic, and therapeutic implications. Even more exciting is the fact that the identification of chromosomal abnormalities directs us to investigate abnormal areas of the genome that may identify the changes responsible for malignant degeneration on a molecular basis.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

McClay EF

subject

Has Abstract

pub_date

1989-08-01 00:00:00

pages

264-72

issue

4

eissn

0093-7754

issn

1532-8708

pii

0093-7754(89)90039-0

journal_volume

16

pub_type

杂志文章,评审
  • Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.

    abstract::The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dombernowsky P,Gehl J,Boesgaard M,Jensen TP,Jensen BV

    更新日期:1996-02-01 00:00:00

  • Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

    abstract::Non-platinum combination regimens have been developed for advanced non--small cell lung cancer using the novel and active agents docetaxel, gemcitabine, vinorelbine, and irinotecan. The aim of these combinations is to equal or exceed the survival benefits achieved with cisplatin doublets while minimizing toxicity. Of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rigas JR

    更新日期:2001-06-01 00:00:00

  • Hodgkin's disease: the role of bone marrow transplantation.

    abstract::Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Vose JM,Bierman PJ,Armitage JO

    更新日期:1990-12-01 00:00:00

  • Pathologic staging of melanoma.

    abstract::The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34116

    authors: Ruiter DJ,Spatz A,van den Oord JJ,Cook MG,Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

    更新日期:2002-08-01 00:00:00

  • Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.

    abstract::Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

    更新日期:1996-04-01 00:00:00

  • Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

    abstract::Angiogenesis is required for multistage carcinogenesis. The inducible enzyme cyclooxygenase-2 (COX-2) is an important mediator of angiogenesis and tumor growth. COX-2 expression occurs in a wide range of preneoplastic and malignant conditions; and the enzyme has been localized to the neoplastic cells, endothelial cell...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.040

    authors: Gately S,Li WW

    更新日期:2004-04-01 00:00:00

  • Response patterns of recurrent glioblastomas treated with tumor-treating fields.

    abstract::Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2014.09.009

    authors: Vymazal J,Wong ET

    更新日期:2014-10-01 00:00:00

  • Prognostic factors in renal carcinoma.

    abstract::Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rini BI,Vogelzang NJ

    更新日期:2000-04-01 00:00:00

  • Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

    abstract::We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2003.50050

    authors: Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

    更新日期:2003-04-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

    abstract::Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Diehl LF,Ketchum LH

    更新日期:1998-02-01 00:00:00

  • Pathologic prognostic factors in esophageal carcinoma.

    abstract::Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Klimstra DS

    更新日期:1994-08-01 00:00:00

  • Treatment of brain metastases of small cell lung cancer with teniposide.

    abstract::Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

    更新日期:1992-04-01 00:00:00

  • Descriptive epidemiology and risk factors for head and neck cancer.

    abstract::Although more common in developing countries, over 11,000 deaths will occur in the United States from head and neck cancer in 2004. Squamous cell carcinomas account for the vast majority of cases in the United States and the majority of these are related to exposure to tobacco and alcohol. Newer data suggest a genetic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.013

    authors: Sturgis EM,Wei Q,Spitz MR

    更新日期:2004-12-01 00:00:00

  • The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.

    abstract::The combination of paclitaxel and carboplatin is now established as the standard first-line chemotherapy regimen for advanced ovarian cancer. Ways in which this standard therapy can be further improved are being investigated, and several approaches have been taken. One approach is to integrate a different cytotoxic ag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.03.015

    authors: Thigpen T

    更新日期:2006-04-01 00:00:00

  • Management of postmenopausal symptoms in breast cancer survivors.

    abstract::With the increasing numbers of breast cancers survivors, menopause, its symptoms, and its physical complications are becoming more prevalent problems in this patient population. Hormonal replacement, which has been the cornerstone therapy of menopausal related symptoms for decades, recently has been shown to increase ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.08.010

    authors: Bruno D,Feeney KJ

    更新日期:2006-12-01 00:00:00

  • The alpha interferons: clinical overview.

    abstract::The clinical development of the recombinant alpha interferons has provided a prototype for the clinical development of biological compounds. With over 5,000 patients now treated with these compounds, some general principles have emerged that have wider implications for phase I-II strategies for testing other biologica...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Spiegel RJ

    更新日期:1987-06-01 00:00:00

  • Obstruction due to malignant tumors.

    abstract::An overview of the causes, the clinical pictures and the management of obstruction in three major organ systems due to primary and secondary malignant neoplasms has been presented. Such obstruction often produces dramatic clinical pictures that require careful, appropriate, and often aggressive therapy if patients are...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sise JG,Crichlow RW

    更新日期:1978-06-01 00:00:00

  • Intrahepatic arterial infusion of chemotherapy: clinical results.

    abstract::Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31680

    authors: Dizon DS,Kemeny NE

    更新日期:2002-04-01 00:00:00

  • The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.

    abstract::The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

    更新日期:1996-08-01 00:00:00

  • Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Manegold C

    更新日期:1998-08-01 00:00:00

  • Surgical adjuvant chemotherapy in non-small cell lung cancer.

    abstract::In two different controlled prospective randomized trials the Lung Cancer Study Group has shown that adjuvant CAP chemotherapy is effective in prolonging the disease-free survival. These studies indicate that the adjuvant chemotherapy has its effect by way of diminishing systemic recurrences and that the adjuvant ther...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Holmes EC

    更新日期:1988-06-01 00:00:00

  • Cellular immunotherapy and cancer.

    abstract::Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.021

    authors: Waller EK

    更新日期:2004-04-01 00:00:00

  • Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.

    abstract::This ongoing study was initiated to determine the feasibility of administering amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) with monomodal high-dose rate (mHDR) brachytherapy and to assess the tolerability and side effects of this combination. To date, 18 patients suitable for prostate implant brachy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.010

    authors: Dziuk T,Senzer N

    更新日期:2003-12-01 00:00:00

  • Treatment specific toxicities: Hormones, antihormones, radiation therapy.

    abstract::Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2019.01.006

    authors: Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

    更新日期:2019-12-01 00:00:00

  • Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hainsworth JD,Greco FA

    更新日期:1995-12-01 00:00:00

  • African American men, prostate cancer early detection examination use, and informed decision-making.

    abstract::It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Myers RE

    更新日期:1999-08-01 00:00:00

  • Antiestrogen therapy of breast cancer.

    abstract::Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast can...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lippman ME

    更新日期:1983-12-01 00:00:00

  • Current strategies for locoregionally advanced unresectable non-small cell lung cancer.

    abstract::Locoregionally advanced unresectable non-small cell lung cancer is defined by bulky primary site disease and/or regionally advanced lymphadenopathy involving the contralateral mediastinum and/or supraclavicular lymph nodes. These tumors are not amenable to curative-intent surgical resection but can be approached with ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Vokes EE,Green MR

    更新日期:1999-10-01 00:00:00